Mezofy

Overview

aripiprazole oral

atypical antipsychotic

• CYP2D6 substrate
• CYP3A4 substrate
• CNS depression
• decreases central histamine effects
• extrapyramidal effects
• hyperglycemic effects
• hyperthermia
• hypotensive effects
• lowers seizure threshold

• drug interactions apply only to oral aripiprazole forms; see other aripiprazole products for potentially relevant interactions
• aripiprazole is a substrate of CYP2D6 and CYP3A4; drug interaction guidance may vary with CYP450 inhibitors if patient is CYP2D6 poor metabolizer (PM)

Avoid/Use Alternative

• aldesleukin
Mezofy (aripiprazole)

+

aldesleukin

1 interaction

Avoid/Use Alternative

aripiprazole oral + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe or life-threatening hypotension (including orthostasis), seizures (additive effects)

• amifampridine
Mezofy (aripiprazole)

+

amifampridine

1 interaction

Avoid/Use Alternative

aripiprazole oral + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• aripiprazole bimonthly injection
Mezofy (aripiprazole)

+

aripiprazole bimonthly injection

1 interaction

Avoid/Use Alternative

aripiprazole oral + aripiprazole bimonthly injection

avoid combo after tx initiation: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole lauroxil
Mezofy (aripiprazole)

+

aripiprazole lauroxil

1 interaction

Avoid/Use Alternative

aripiprazole oral + aripiprazole lauroxil

avoid combo after tx initiation: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole monthly injection
Mezofy (aripiprazole)

+

aripiprazole monthly injection

1 interaction

Avoid/Use Alternative

aripiprazole oral + aripiprazole monthly injection

avoid combo after tx initiation: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole oral
Mezofy (aripiprazole)

+

aripiprazole oral

1 interaction

Avoid/Use Alternative

aripiprazole oral + aripiprazole oral

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• asenapine
Mezofy (aripiprazole)

+

asenapine

1 interaction

Avoid/Use Alternative

aripiprazole oral + asenapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• brexpiprazole
Mezofy (aripiprazole)

+

brexpiprazole

1 interaction

Avoid/Use Alternative

aripiprazole oral + brexpiprazole

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• butalbital
Mezofy (aripiprazole)

+

butalbital

1 interaction

Avoid/Use Alternative

aripiprazole oral + butalbital

avoid combo: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• cariprazine
Mezofy (aripiprazole)

+

cariprazine

1 interaction

Avoid/Use Alternative

aripiprazole oral + cariprazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• clonidine
Mezofy (aripiprazole)

+

clonidine

1 interaction

Avoid/Use Alternative

aripiprazole oral + clonidine

if ADHD use, avoid combo; otherwise, monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• clozapine
Mezofy (aripiprazole)

+

clozapine

1 interaction

Avoid/Use Alternative

aripiprazole oral + clozapine

use alternative or monitor BP, HR: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, seizures, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• codeine
Mezofy (aripiprazole)

+

codeine

1 interaction

Avoid/Use Alternative

aripiprazole oral + codeine

avoid combo if antitussive use; otherwise, monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• doxylamine
Mezofy (aripiprazole)

+

doxylamine

1 interaction

Avoid/Use Alternative

aripiprazole oral + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ethanol (alcoholic beverage)
Mezofy (aripiprazole)

+

ethanol (alcoholic beverage)

1 interaction

Avoid/Use Alternative

aripiprazole oral + ethanol (alcoholic beverage)

avoid combo: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis (additive effects)

• ethanol injection
Mezofy (aripiprazole)

+

ethanol injection

1 interaction

Avoid/Use Alternative

aripiprazole oral + ethanol injection

use alternative or monitor respiratory rate, BP: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis (additive effects)

• haloperidol
Mezofy (aripiprazole)

+

haloperidol

1 interaction

Avoid/Use Alternative

aripiprazole oral + haloperidol

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hypotension, including orthostasis (additive effects)

• hydrocodone
Mezofy (aripiprazole)

+

hydrocodone

1 interaction

Avoid/Use Alternative

aripiprazole oral + hydrocodone

avoid combo if antitussive use; otherwise, monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• iloperidone
Mezofy (aripiprazole)

+

iloperidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + iloperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• isocarboxazid
Mezofy (aripiprazole)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

aripiprazole oral + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• ivosidenib
Mezofy (aripiprazole)

+

ivosidenib

1 interaction

Avoid/Use Alternative

aripiprazole oral + ivosidenib

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• kava
Mezofy (aripiprazole)

+

kava

1 interaction

Avoid/Use Alternative

aripiprazole oral + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• kratom
Mezofy (aripiprazole)

+

kratom

1 interaction

Avoid/Use Alternative

aripiprazole oral + kratom

use alternative or monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• lofexidine
Mezofy (aripiprazole)

+

lofexidine

1 interaction

Avoid/Use Alternative

aripiprazole oral + lofexidine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• lumateperone
Mezofy (aripiprazole)

+

lumateperone

1 interaction

Avoid/Use Alternative

aripiprazole oral + lumateperone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• lurasidone
Mezofy (aripiprazole)

+

lurasidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + lurasidone

use alternative or monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• metaxalone
Mezofy (aripiprazole)

+

metaxalone

1 interaction

Avoid/Use Alternative

aripiprazole oral + metaxalone

use alternative or monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• metoclopramide
Mezofy (aripiprazole)

+

metoclopramide

1 interaction

Avoid/Use Alternative

aripiprazole oral + metoclopramide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, neuroleptic malignant syndrome, extrapyramidal symptoms (additive effects)

• midazolam
Mezofy (aripiprazole)

+

midazolam

1 interaction

Avoid/Use Alternative

aripiprazole oral + midazolam

use alternative or monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• milsaperidone
Mezofy (aripiprazole)

+

milsaperidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + milsaperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• olanzapine
Mezofy (aripiprazole)

+

olanzapine

1 interaction

Avoid/Use Alternative

aripiprazole oral + olanzapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• oxybate
Mezofy (aripiprazole)

+

oxybate

1 interaction

Avoid/Use Alternative

aripiprazole oral + oxybate

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

• paliperidone
Mezofy (aripiprazole)

+

paliperidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + paliperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• phenelzine
Mezofy (aripiprazole)

+

phenelzine

1 interaction

Avoid/Use Alternative

aripiprazole oral + phenelzine

use alternative: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• pitolisant
Mezofy (aripiprazole)

+

pitolisant

1 interaction

Avoid/Use Alternative

aripiprazole oral + pitolisant

avoid combo: combo may decr. pitolisant efficacy (antagonistic effects)

• promethazine
Mezofy (aripiprazole)

+

promethazine

1 interaction

Avoid/Use Alternative

aripiprazole oral + promethazine

use alternative or monitor respiratory rate, BP; decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, seizures, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis (additive effects)

• quetiapine
Mezofy (aripiprazole)

+

quetiapine

1 interaction

Avoid/Use Alternative

aripiprazole oral + quetiapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• risperidone
Mezofy (aripiprazole)

+

risperidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + risperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• ropeginterferon alfa-2b
Mezofy (aripiprazole)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

aripiprazole oral + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Mezofy (aripiprazole)

+

scopolamine

1 interaction

Avoid/Use Alternative

aripiprazole oral + scopolamine

use alternative: combo may increase risk of CNS depression, psychomotor impairment, hyperthermia, including life-threatening (additive effects)

• thalidomide
Mezofy (aripiprazole)

+

thalidomide

1 interaction

Avoid/Use Alternative

aripiprazole oral + thalidomide

use alternative or monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• tradipitant
Mezofy (aripiprazole)

+

tradipitant

1 interaction

Avoid/Use Alternative

aripiprazole oral + tradipitant

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tranylcypromine
Mezofy (aripiprazole)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

aripiprazole oral + tranylcypromine

use alternative or monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• trimethobenzamide
Mezofy (aripiprazole)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

aripiprazole oral + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• ziprasidone
Mezofy (aripiprazole)

+

ziprasidone

1 interaction

Avoid/Use Alternative

aripiprazole oral + ziprasidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• zuranolone
Mezofy (aripiprazole)

+

zuranolone

1 interaction

Avoid/Use Alternative

aripiprazole oral + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• abiraterone acetate
Mezofy (aripiprazole)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

aripiprazole oral + abiraterone acetate

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• acarbose
Mezofy (aripiprazole)

+

acarbose

1 interaction

Monitor/Modify Tx

aripiprazole oral + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acebutolol
Mezofy (aripiprazole)

+

acebutolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + acebutolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• adagrasib
Mezofy (aripiprazole)

+

adagrasib

1 interaction

Monitor/Modify Tx

aripiprazole oral + adagrasib

consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• alfentanil
Mezofy (aripiprazole)

+

alfentanil

1 interaction

Monitor/Modify Tx

aripiprazole oral + alfentanil

monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• alfuzosin
Mezofy (aripiprazole)

+

alfuzosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + alfuzosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• aliskiren
Mezofy (aripiprazole)

+

aliskiren

1 interaction

Monitor/Modify Tx

aripiprazole oral + aliskiren

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• alogliptin
Mezofy (aripiprazole)

+

alogliptin

1 interaction

Monitor/Modify Tx

aripiprazole oral + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• alprazolam
Mezofy (aripiprazole)

+

alprazolam

1 interaction

Monitor/Modify Tx

aripiprazole oral + alprazolam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• alprostadil intracavernous
Mezofy (aripiprazole)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

aripiprazole oral + alprostadil intracavernous

monitor BP: combo may increase risk of hypotension, including orthostasis (additive effects)

• amantadine
Mezofy (aripiprazole)

+

amantadine

1 interaction

Monitor/Modify Tx

aripiprazole oral + amantadine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amifostine
Mezofy (aripiprazole)

+

amifostine

1 interaction

Monitor/Modify Tx

aripiprazole oral + amifostine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• amiloride
Mezofy (aripiprazole)

+

amiloride

1 interaction

Monitor/Modify Tx

aripiprazole oral + amiloride

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• amitriptyline
Mezofy (aripiprazole)

+

amitriptyline

1 interaction

Monitor/Modify Tx

aripiprazole oral + amitriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• amlodipine
Mezofy (aripiprazole)

+

amlodipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + amlodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• amoxapine
Mezofy (aripiprazole)

+

amoxapine

1 interaction

Monitor/Modify Tx

aripiprazole oral + amoxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• apalutamide
Mezofy (aripiprazole)

+

apalutamide

1 interaction

Monitor/Modify Tx

aripiprazole oral + apalutamide

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• apomorphine
Mezofy (aripiprazole)

+

apomorphine

1 interaction

Monitor/Modify Tx

aripiprazole oral + apomorphine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• apraclonidine ophthalmic
Mezofy (aripiprazole)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + apraclonidine ophthalmic

monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• aprepitant
Mezofy (aripiprazole)

+

aprepitant

1 interaction

Monitor/Modify Tx

aripiprazole oral + aprepitant

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo with aprepitant 3-day regimen may incr. aripiprazole levels, risk of adverse effects; aprepitant single dose-regimen OK (hepatic metabolism inhibited)

• aprocitentan
Mezofy (aripiprazole)

+

aprocitentan

1 interaction

Monitor/Modify Tx

aripiprazole oral + aprocitentan

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• articaine
Mezofy (aripiprazole)

+

articaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + articaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• atazanavir
Mezofy (aripiprazole)

+

atazanavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + atazanavir

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• atenolol
Mezofy (aripiprazole)

+

atenolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + atenolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• avacopan
Mezofy (aripiprazole)

+

avacopan

1 interaction

Monitor/Modify Tx

aripiprazole oral + avacopan

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• avanafil
Mezofy (aripiprazole)

+

avanafil

1 interaction

Monitor/Modify Tx

aripiprazole oral + avanafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• azilsartan medoxomil
Mezofy (aripiprazole)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

aripiprazole oral + azilsartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• baclofen intrathecal
Mezofy (aripiprazole)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

aripiprazole oral + baclofen intrathecal

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• benazepril
Mezofy (aripiprazole)

+

benazepril

1 interaction

Monitor/Modify Tx

aripiprazole oral + benazepril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• berberine
Mezofy (aripiprazole)

+

berberine

1 interaction

Monitor/Modify Tx

aripiprazole oral + berberine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• berotralstat
Mezofy (aripiprazole)

+

berotralstat

1 interaction

Monitor/Modify Tx

aripiprazole oral + berotralstat

consider decr. PO aripiprazole dose; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• betaxolol
Mezofy (aripiprazole)

+

betaxolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + betaxolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• betaxolol ophthalmic
Mezofy (aripiprazole)

+

betaxolol ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + betaxolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• bethanechol
Mezofy (aripiprazole)

+

bethanechol

1 interaction

Monitor/Modify Tx

aripiprazole oral + bethanechol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• bexagliflozin
Mezofy (aripiprazole)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + bexagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bisoprolol
Mezofy (aripiprazole)

+

bisoprolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + bisoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• bortezomib
Mezofy (aripiprazole)

+

bortezomib

1 interaction

Monitor/Modify Tx

aripiprazole oral + bortezomib

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• brimonidine ophthalmic
Mezofy (aripiprazole)

+

brimonidine ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + brimonidine ophthalmic

monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• brimonidine topical
Mezofy (aripiprazole)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

aripiprazole oral + brimonidine topical

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• bromocriptine
Mezofy (aripiprazole)

+

bromocriptine

1 interaction

Monitor/Modify Tx

aripiprazole oral + bromocriptine

monitor BP, glucose in type 2 diabetes mellitus pts: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bumetanide
Mezofy (aripiprazole)

+

bumetanide

1 interaction

Monitor/Modify Tx

aripiprazole oral + bumetanide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• bupivacaine
Mezofy (aripiprazole)

+

bupivacaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + bupivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• bupivacaine liposomal
Mezofy (aripiprazole)

+

bupivacaine liposomal

1 interaction

Monitor/Modify Tx

aripiprazole oral + bupivacaine liposomal

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• buprenorphine
Mezofy (aripiprazole)

+

buprenorphine

1 interaction

Monitor/Modify Tx

aripiprazole oral + buprenorphine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• bupropion
Mezofy (aripiprazole)

+

bupropion

1 interaction

Monitor/Modify Tx

aripiprazole oral + bupropion

consider lower bupropion doses; decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of seizures, other adverse effects (hepatic metabolism inhibited; additive effects)

• butorphanol
Mezofy (aripiprazole)

+

butorphanol

1 interaction

Monitor/Modify Tx

aripiprazole oral + butorphanol

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• cabergoline
Mezofy (aripiprazole)

+

cabergoline

1 interaction

Monitor/Modify Tx

aripiprazole oral + cabergoline

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• canagliflozin
Mezofy (aripiprazole)

+

canagliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + canagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• candesartan cilexetil
Mezofy (aripiprazole)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

aripiprazole oral + candesartan cilexetil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• cannabis
Mezofy (aripiprazole)

+

cannabis

1 interaction

Monitor/Modify Tx

aripiprazole oral + cannabis

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• capivasertib
Mezofy (aripiprazole)

+

capivasertib

1 interaction

Monitor/Modify Tx

aripiprazole oral + capivasertib

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• captopril
Mezofy (aripiprazole)

+

captopril

1 interaction

Monitor/Modify Tx

aripiprazole oral + captopril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• carbamazepine
Mezofy (aripiprazole)

+

carbamazepine

1 interaction

Monitor/Modify Tx

aripiprazole oral + carbamazepine

monitor BP; double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS depression, psychomotor impairment, hypotension, including syncope; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• carteolol ophthalmic
Mezofy (aripiprazole)

+

carteolol ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + carteolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• carvedilol
Mezofy (aripiprazole)

+

carvedilol

1 interaction

Monitor/Modify Tx

aripiprazole oral + carvedilol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• ceritinib
Mezofy (aripiprazole)

+

ceritinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + ceritinib

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Mezofy (aripiprazole)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

aripiprazole oral + chloramphenicol

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• chlordiazepoxide
Mezofy (aripiprazole)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

aripiprazole oral + chlordiazepoxide

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• chloroprocaine
Mezofy (aripiprazole)

+

chloroprocaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + chloroprocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• chlorothiazide
Mezofy (aripiprazole)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

aripiprazole oral + chlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• chlorpromazine
Mezofy (aripiprazole)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + chlorpromazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• chlorthalidone
Mezofy (aripiprazole)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

aripiprazole oral + chlorthalidone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• cilostazol
Mezofy (aripiprazole)

+

cilostazol

1 interaction

Monitor/Modify Tx

aripiprazole oral + cilostazol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• cinacalcet
Mezofy (aripiprazole)

+

cinacalcet

1 interaction

Monitor/Modify Tx

aripiprazole oral + cinacalcet

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Mezofy (aripiprazole)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

aripiprazole oral + ciprofloxacin

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• clarithromycin
Mezofy (aripiprazole)

+

clarithromycin

1 interaction

Monitor/Modify Tx

aripiprazole oral + clarithromycin

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• clevidipine
Mezofy (aripiprazole)

+

clevidipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + clevidipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• clobazam
Mezofy (aripiprazole)

+

clobazam

1 interaction

Monitor/Modify Tx

aripiprazole oral + clobazam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• clofarabine
Mezofy (aripiprazole)

+

clofarabine

1 interaction

Monitor/Modify Tx

aripiprazole oral + clofarabine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• clofazimine
Mezofy (aripiprazole)

+

clofazimine

1 interaction

Monitor/Modify Tx

aripiprazole oral + clofazimine

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• clomipramine
Mezofy (aripiprazole)

+

clomipramine

1 interaction

Monitor/Modify Tx

aripiprazole oral + clomipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, seizures, hyperthermia, hypotension, including orthostasis (additive effects)

• clonazepam
Mezofy (aripiprazole)

+

clonazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + clonazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• clorazepate
Mezofy (aripiprazole)

+

clorazepate

1 interaction

Monitor/Modify Tx

aripiprazole oral + clorazepate

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• cobicistat
Mezofy (aripiprazole)

+

cobicistat

1 interaction

Monitor/Modify Tx

aripiprazole oral + cobicistat

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• coenzyme Q-10
Mezofy (aripiprazole)

+

coenzyme Q-10

1 interaction

Monitor/Modify Tx

aripiprazole oral + coenzyme Q-10

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• colesevelam
Mezofy (aripiprazole)

+

colesevelam

1 interaction

Monitor/Modify Tx

aripiprazole oral + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• conivaptan
Mezofy (aripiprazole)

+

conivaptan

1 interaction

Monitor/Modify Tx

aripiprazole oral + conivaptan

consider decr. PO aripiprazole dose during and x7 days after conivaptan tx; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75% during and x7 days after conivaptan tx; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• crizotinib
Mezofy (aripiprazole)

+

crizotinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + crizotinib

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• cyclosporine
Mezofy (aripiprazole)

+

cyclosporine

1 interaction

Monitor/Modify Tx

aripiprazole oral + cyclosporine

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• dacomitinib
Mezofy (aripiprazole)

+

dacomitinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + dacomitinib

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• danazol
Mezofy (aripiprazole)

+

danazol

1 interaction

Monitor/Modify Tx

aripiprazole oral + danazol

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• dapagliflozin
Mezofy (aripiprazole)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + dapagliflozin

monitor glucose, BP: combo may decr. antidiabetic agent efficacy; may incr. risk of hypotension, including orthostasis (antagonistic effects; additive effects)

• daridorexant
Mezofy (aripiprazole)

+

daridorexant

1 interaction

Monitor/Modify Tx

aripiprazole oral + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darunavir
Mezofy (aripiprazole)

+

darunavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + darunavir

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• denileukin diftitox
Mezofy (aripiprazole)

+

denileukin diftitox

1 interaction

Monitor/Modify Tx

aripiprazole oral + denileukin diftitox

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• desflurane
Mezofy (aripiprazole)

+

desflurane

1 interaction

Monitor/Modify Tx

aripiprazole oral + desflurane

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• desipramine
Mezofy (aripiprazole)

+

desipramine

1 interaction

Monitor/Modify Tx

aripiprazole oral + desipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• dexmedetomidine
Mezofy (aripiprazole)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

aripiprazole oral + dexmedetomidine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine injection
Mezofy (aripiprazole)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

aripiprazole oral + dexmedetomidine injection

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe or life-threatening hypotension, including orthostasis (additive effects)

• diazepam
Mezofy (aripiprazole)

+

diazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + diazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• dihydrocodeine
Mezofy (aripiprazole)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

aripiprazole oral + dihydrocodeine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• diltiazem
Mezofy (aripiprazole)

+

diltiazem

1 interaction

Monitor/Modify Tx

aripiprazole oral + diltiazem

monitor BP; consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of hypotension (including orthostasis), other adverse effects (hepatic metabolism inhibited, additive effects)

• dinutuximab
Mezofy (aripiprazole)

+

dinutuximab

1 interaction

Monitor/Modify Tx

aripiprazole oral + dinutuximab

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• dipyridamole
Mezofy (aripiprazole)

+

dipyridamole

1 interaction

Monitor/Modify Tx

aripiprazole oral + dipyridamole

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• doxazosin
Mezofy (aripiprazole)

+

doxazosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + doxazosin

monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• doxepin
Mezofy (aripiprazole)

+

doxepin

1 interaction

Monitor/Modify Tx

aripiprazole oral + doxepin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• dronabinol
Mezofy (aripiprazole)

+

dronabinol

1 interaction

Monitor/Modify Tx

aripiprazole oral + dronabinol

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• dronedarone
Mezofy (aripiprazole)

+

dronedarone

1 interaction

Monitor/Modify Tx

aripiprazole oral + dronedarone

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• droperidol
Mezofy (aripiprazole)

+

droperidol

1 interaction

Monitor/Modify Tx

aripiprazole oral + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dulaglutide
Mezofy (aripiprazole)

+

dulaglutide

1 interaction

Monitor/Modify Tx

aripiprazole oral + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duloxetine
Mezofy (aripiprazole)

+

duloxetine

1 interaction

Monitor/Modify Tx

aripiprazole oral + duloxetine

monitor BP; consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of CNS depression, psychomotor impairment, hypotension (including orthostasis), other adverse effects (hepatic metabolism inhibited, additive effects)

• duvelisib
Mezofy (aripiprazole)

+

duvelisib

1 interaction

Monitor/Modify Tx

aripiprazole oral + duvelisib

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• eliglustat
Mezofy (aripiprazole)

+

eliglustat

1 interaction

Monitor/Modify Tx

aripiprazole oral + eliglustat

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• empagliflozin
Mezofy (aripiprazole)

+

empagliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + empagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• enalapril
Mezofy (aripiprazole)

+

enalapril

1 interaction

Monitor/Modify Tx

aripiprazole oral + enalapril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• enalaprilat
Mezofy (aripiprazole)

+

enalaprilat

1 interaction

Monitor/Modify Tx

aripiprazole oral + enalaprilat

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• encorafenib
Mezofy (aripiprazole)

+

encorafenib

1 interaction

Monitor/Modify Tx

aripiprazole oral + encorafenib

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• entacapone
Mezofy (aripiprazole)

+

entacapone

1 interaction

Monitor/Modify Tx

aripiprazole oral + entacapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• entrectinib
Mezofy (aripiprazole)

+

entrectinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + entrectinib

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• enzalutamide
Mezofy (aripiprazole)

+

enzalutamide

1 interaction

Monitor/Modify Tx

aripiprazole oral + enzalutamide

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• eplerenone
Mezofy (aripiprazole)

+

eplerenone

1 interaction

Monitor/Modify Tx

aripiprazole oral + eplerenone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• epoprostenol
Mezofy (aripiprazole)

+

epoprostenol

1 interaction

Monitor/Modify Tx

aripiprazole oral + epoprostenol

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• ertugliflozin
Mezofy (aripiprazole)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + ertugliflozin

monitor glucose, BP: combo may decr. antidiabetic agent efficacy; may incr. risk of hypotension, including orthostasis (antagonistic effects; additive effects)

• erythromycin
Mezofy (aripiprazole)

+

erythromycin

1 interaction

Monitor/Modify Tx

aripiprazole oral + erythromycin

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• esketamine
Mezofy (aripiprazole)

+

esketamine

1 interaction

Monitor/Modify Tx

aripiprazole oral + esketamine

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• esmolol
Mezofy (aripiprazole)

+

esmolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + esmolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• estazolam
Mezofy (aripiprazole)

+

estazolam

1 interaction

Monitor/Modify Tx

aripiprazole oral + estazolam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• eszopiclone
Mezofy (aripiprazole)

+

eszopiclone

1 interaction

Monitor/Modify Tx

aripiprazole oral + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethacrynic acid
Mezofy (aripiprazole)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

aripiprazole oral + ethacrynic acid

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• ethanol (in some formulations)
Mezofy (aripiprazole)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

aripiprazole oral + ethanol (in some formulations)

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etomidate
Mezofy (aripiprazole)

+

etomidate

1 interaction

Monitor/Modify Tx

aripiprazole oral + etomidate

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etripamil nasal
Mezofy (aripiprazole)

+

etripamil nasal

1 interaction

Monitor/Modify Tx

aripiprazole oral + etripamil nasal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• exenatide
Mezofy (aripiprazole)

+

exenatide

1 interaction

Monitor/Modify Tx

aripiprazole oral + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fedratinib
Mezofy (aripiprazole)

+

fedratinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + fedratinib

consider decr. PO aripiprazole dose; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• felodipine
Mezofy (aripiprazole)

+

felodipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + felodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• fenoldopam
Mezofy (aripiprazole)

+

fenoldopam

1 interaction

Monitor/Modify Tx

aripiprazole oral + fenoldopam

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• fentanyl
Mezofy (aripiprazole)

+

fentanyl

1 interaction

Monitor/Modify Tx

aripiprazole oral + fentanyl

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ferumoxytol
Mezofy (aripiprazole)

+

ferumoxytol

1 interaction

Monitor/Modify Tx

aripiprazole oral + ferumoxytol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• flaxseed
Mezofy (aripiprazole)

+

flaxseed

1 interaction

Monitor/Modify Tx

aripiprazole oral + flaxseed

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• flibanserin
Mezofy (aripiprazole)

+

flibanserin

1 interaction

Monitor/Modify Tx

aripiprazole oral + flibanserin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• fluconazole
Mezofy (aripiprazole)

+

fluconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + fluconazole

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• fluoxetine
Mezofy (aripiprazole)

+

fluoxetine

1 interaction

Monitor/Modify Tx

aripiprazole oral + fluoxetine

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluphenazine
Mezofy (aripiprazole)

+

fluphenazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + fluphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis (additive effects)

• flurazepam
Mezofy (aripiprazole)

+

flurazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + flurazepam

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• fosamprenavir
Mezofy (aripiprazole)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + fosamprenavir

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• fosinopril
Mezofy (aripiprazole)

+

fosinopril

1 interaction

Monitor/Modify Tx

aripiprazole oral + fosinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• foslevodopa
Mezofy (aripiprazole)

+

foslevodopa

1 interaction

Monitor/Modify Tx

aripiprazole oral + foslevodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• fosphenytoin
Mezofy (aripiprazole)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

aripiprazole oral + fosphenytoin

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• furosemide
Mezofy (aripiprazole)

+

furosemide

1 interaction

Monitor/Modify Tx

aripiprazole oral + furosemide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• gabapentin
Mezofy (aripiprazole)

+

gabapentin

1 interaction

Monitor/Modify Tx

aripiprazole oral + gabapentin

monitor respiratory rate; consider decreasing gabapentin dose: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decrease seizure threshold)

• gabapentin enacarbil
Mezofy (aripiprazole)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

aripiprazole oral + gabapentin enacarbil

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• garlic
Mezofy (aripiprazole)

+

garlic

1 interaction

Monitor/Modify Tx

aripiprazole oral + garlic

monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, including orthostasis (additive effects)

• gilteritinib
Mezofy (aripiprazole)

+

gilteritinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + gilteritinib

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• givosiran
Mezofy (aripiprazole)

+

givosiran

1 interaction

Monitor/Modify Tx

aripiprazole oral + givosiran

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited; givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glimepiride
Mezofy (aripiprazole)

+

glimepiride

1 interaction

Monitor/Modify Tx

aripiprazole oral + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Mezofy (aripiprazole)

+

glipizide

1 interaction

Monitor/Modify Tx

aripiprazole oral + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Mezofy (aripiprazole)

+

glyburide

1 interaction

Monitor/Modify Tx

aripiprazole oral + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• grapefruit
Mezofy (aripiprazole)

+

grapefruit

1 interaction

Monitor/Modify Tx

aripiprazole oral + grapefruit

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (GI metabolism inhibited)

• guanfacine
Mezofy (aripiprazole)

+

guanfacine

1 interaction

Monitor/Modify Tx

aripiprazole oral + guanfacine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• hydralazine
Mezofy (aripiprazole)

+

hydralazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + hydralazine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• hydrochlorothiazide
Mezofy (aripiprazole)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

aripiprazole oral + hydrochlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• hydromorphone
Mezofy (aripiprazole)

+

hydromorphone

1 interaction

Monitor/Modify Tx

aripiprazole oral + hydromorphone

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• hydroxyzine
Mezofy (aripiprazole)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

aripiprazole oral + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• idelalisib
Mezofy (aripiprazole)

+

idelalisib

1 interaction

Monitor/Modify Tx

aripiprazole oral + idelalisib

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• ifosfamide
Mezofy (aripiprazole)

+

ifosfamide

1 interaction

Monitor/Modify Tx

aripiprazole oral + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloprost
Mezofy (aripiprazole)

+

iloprost

1 interaction

Monitor/Modify Tx

aripiprazole oral + iloprost

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• imatinib
Mezofy (aripiprazole)

+

imatinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + imatinib

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• imipramine
Mezofy (aripiprazole)

+

imipramine

1 interaction

Monitor/Modify Tx

aripiprazole oral + imipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• indapamide
Mezofy (aripiprazole)

+

indapamide

1 interaction

Monitor/Modify Tx

aripiprazole oral + indapamide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• insulin
Mezofy (aripiprazole)

+

insulin

1 interaction

Monitor/Modify Tx

aripiprazole oral + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• iohexol
Mezofy (aripiprazole)

+

iohexol

1 interaction

Monitor/Modify Tx

aripiprazole oral + iohexol

if intrathecal iohexol use, D/C aripiprazole at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Mezofy (aripiprazole)

+

iopamidol

1 interaction

Monitor/Modify Tx

aripiprazole oral + iopamidol

caution advised if intrathecal iopamidol use; consider holding aripiprazole at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Mezofy (aripiprazole)

+

irbesartan

1 interaction

Monitor/Modify Tx

aripiprazole oral + irbesartan

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• iron sucrose
Mezofy (aripiprazole)

+

iron sucrose

1 interaction

Monitor/Modify Tx

aripiprazole oral + iron sucrose

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• isavuconazonium
Mezofy (aripiprazole)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

aripiprazole oral + isavuconazonium

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• isoflurane
Mezofy (aripiprazole)

+

isoflurane

1 interaction

Monitor/Modify Tx

aripiprazole oral + isoflurane

monitor BP, respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• isosorbide dinitrate
Mezofy (aripiprazole)

+

isosorbide dinitrate

1 interaction

Monitor/Modify Tx

aripiprazole oral + isosorbide dinitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isosorbide mononitrate
Mezofy (aripiprazole)

+

isosorbide mononitrate

1 interaction

Monitor/Modify Tx

aripiprazole oral + isosorbide mononitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isradipine
Mezofy (aripiprazole)

+

isradipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + isradipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• itraconazole
Mezofy (aripiprazole)

+

itraconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + itraconazole

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• ketamine
Mezofy (aripiprazole)

+

ketamine

1 interaction

Monitor/Modify Tx

aripiprazole oral + ketamine

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• ketoconazole
Mezofy (aripiprazole)

+

ketoconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + ketoconazole

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• labetalol
Mezofy (aripiprazole)

+

labetalol

1 interaction

Monitor/Modify Tx

aripiprazole oral + labetalol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• landiolol
Mezofy (aripiprazole)

+

landiolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + landiolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• lefamulin
Mezofy (aripiprazole)

+

lefamulin

1 interaction

Monitor/Modify Tx

aripiprazole oral + lefamulin

ORAL LEFAMULIN: consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use; IV lefamulin use OK: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• lemborexant
Mezofy (aripiprazole)

+

lemborexant

1 interaction

Monitor/Modify Tx

aripiprazole oral + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lenacapavir
Mezofy (aripiprazole)

+

lenacapavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + lenacapavir

consider decr. PO aripiprazole dose during and x9mo after lenacapavir tx; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75% during and x9mo after lenacapavir tx; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• letermovir
Mezofy (aripiprazole)

+

letermovir

1 interaction

Monitor/Modify Tx

aripiprazole oral + letermovir

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• levobunolol ophthalmic
Mezofy (aripiprazole)

+

levobunolol ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + levobunolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• levodopa
Mezofy (aripiprazole)

+

levodopa

1 interaction

Monitor/Modify Tx

aripiprazole oral + levodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• levoketoconazole
Mezofy (aripiprazole)

+

levoketoconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + levoketoconazole

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• levorphanol
Mezofy (aripiprazole)

+

levorphanol

1 interaction

Monitor/Modify Tx

aripiprazole oral + levorphanol

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• lidocaine
Mezofy (aripiprazole)

+

lidocaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + lidocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• linagliptin
Mezofy (aripiprazole)

+

linagliptin

1 interaction

Monitor/Modify Tx

aripiprazole oral + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Mezofy (aripiprazole)

+

liraglutide

1 interaction

Monitor/Modify Tx

aripiprazole oral + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lisinopril
Mezofy (aripiprazole)

+

lisinopril

1 interaction

Monitor/Modify Tx

aripiprazole oral + lisinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• lithium
Mezofy (aripiprazole)

+

lithium

1 interaction

Monitor/Modify Tx

aripiprazole oral + lithium

D/C one or both drugs if encephalopathy occurs: combo may incr. risk of encephalopathic syndrome, extrapyramidal symptoms (additive effects)

• lixisenatide
Mezofy (aripiprazole)

+

lixisenatide

1 interaction

Monitor/Modify Tx

aripiprazole oral + lixisenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lonafarnib
Mezofy (aripiprazole)

+

lonafarnib

1 interaction

Monitor/Modify Tx

aripiprazole oral + lonafarnib

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• lopinavir/ritonavir
Mezofy (aripiprazole)

+

lopinavir/ ritonavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + lopinavir/ ritonavir

consider aripiprazole dose adjustment: combo may incr. or decr. aripiprazole levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• lorazepam
Mezofy (aripiprazole)

+

lorazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + lorazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• losartan
Mezofy (aripiprazole)

+

losartan

1 interaction

Monitor/Modify Tx

aripiprazole oral + losartan

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• loxapine
Mezofy (aripiprazole)

+

loxapine

1 interaction

Monitor/Modify Tx

aripiprazole oral + loxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• lubiprostone
Mezofy (aripiprazole)

+

lubiprostone

1 interaction

Monitor/Modify Tx

aripiprazole oral + lubiprostone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lumacaftor/ivacaftor
Mezofy (aripiprazole)

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

aripiprazole oral + lumacaftor/ ivacaftor

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• magnesium sulfate
Mezofy (aripiprazole)

+

magnesium sulfate

1 interaction

Monitor/Modify Tx

aripiprazole oral + magnesium sulfate

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• maraviroc
Mezofy (aripiprazole)

+

maraviroc

1 interaction

Monitor/Modify Tx

aripiprazole oral + maraviroc

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• mavorixafor
Mezofy (aripiprazole)

+

mavorixafor

1 interaction

Monitor/Modify Tx

aripiprazole oral + mavorixafor

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• meperidine
Mezofy (aripiprazole)

+

meperidine

1 interaction

Monitor/Modify Tx

aripiprazole oral + meperidine

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• mepivacaine
Mezofy (aripiprazole)

+

mepivacaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + mepivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• metformin
Mezofy (aripiprazole)

+

metformin

1 interaction

Monitor/Modify Tx

aripiprazole oral + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• methadone
Mezofy (aripiprazole)

+

methadone

1 interaction

Monitor/Modify Tx

aripiprazole oral + methadone

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• methohexital
Mezofy (aripiprazole)

+

methohexital

1 interaction

Monitor/Modify Tx

aripiprazole oral + methohexital

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• methyldopa
Mezofy (aripiprazole)

+

methyldopa

1 interaction

Monitor/Modify Tx

aripiprazole oral + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• methylene blue injection
Mezofy (aripiprazole)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

aripiprazole oral + methylene blue injection

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• metolazone
Mezofy (aripiprazole)

+

metolazone

1 interaction

Monitor/Modify Tx

aripiprazole oral + metolazone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• metoprolol
Mezofy (aripiprazole)

+

metoprolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + metoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• mifepristone
Mezofy (aripiprazole)

+

mifepristone

1 interaction

Monitor/Modify Tx

aripiprazole oral + mifepristone

decr. PO aripiprazole dose 50% during and x14 days after daily mifepristone; if CYP2D6 PM or combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75% during and x14 days after daily mifepristone; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• miglitol
Mezofy (aripiprazole)

+

miglitol

1 interaction

Monitor/Modify Tx

aripiprazole oral + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• milrinone
Mezofy (aripiprazole)

+

milrinone

1 interaction

Monitor/Modify Tx

aripiprazole oral + milrinone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• minoxidil
Mezofy (aripiprazole)

+

minoxidil

1 interaction

Monitor/Modify Tx

aripiprazole oral + minoxidil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• mirabegron
Mezofy (aripiprazole)

+

mirabegron

1 interaction

Monitor/Modify Tx

aripiprazole oral + mirabegron

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• mirtazapine
Mezofy (aripiprazole)

+

mirtazapine

1 interaction

Monitor/Modify Tx

aripiprazole oral + mirtazapine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• mitotane
Mezofy (aripiprazole)

+

mitotane

1 interaction

Monitor/Modify Tx

aripiprazole oral + mitotane

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• moexipril
Mezofy (aripiprazole)

+

moexipril

1 interaction

Monitor/Modify Tx

aripiprazole oral + moexipril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• molindone
Mezofy (aripiprazole)

+

molindone

1 interaction

Monitor/Modify Tx

aripiprazole oral + molindone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis (additive effects)

• morphine
Mezofy (aripiprazole)

+

morphine

1 interaction

Monitor/Modify Tx

aripiprazole oral + morphine

monitor BP, respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nadolol
Mezofy (aripiprazole)

+

nadolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + nadolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nalbuphine
Mezofy (aripiprazole)

+

nalbuphine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nalbuphine

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• nateglinide
Mezofy (aripiprazole)

+

nateglinide

1 interaction

Monitor/Modify Tx

aripiprazole oral + nateglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nattokinase
Mezofy (aripiprazole)

+

nattokinase

1 interaction

Monitor/Modify Tx

aripiprazole oral + nattokinase

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• naxitamab
Mezofy (aripiprazole)

+

naxitamab

1 interaction

Monitor/Modify Tx

aripiprazole oral + naxitamab

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nebivolol
Mezofy (aripiprazole)

+

nebivolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + nebivolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nefazodone
Mezofy (aripiprazole)

+

nefazodone

1 interaction

Monitor/Modify Tx

aripiprazole oral + nefazodone

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• nelarabine
Mezofy (aripiprazole)

+

nelarabine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelfinavir
Mezofy (aripiprazole)

+

nelfinavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + nelfinavir

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• netupitant
Mezofy (aripiprazole)

+

netupitant

1 interaction

Monitor/Modify Tx

aripiprazole oral + netupitant

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• niacin (vitamin B3)
Mezofy (aripiprazole)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

aripiprazole oral + niacin (vitamin B3)

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nicardipine
Mezofy (aripiprazole)

+

nicardipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nicardipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nifedipine
Mezofy (aripiprazole)

+

nifedipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nifedipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nilotinib
Mezofy (aripiprazole)

+

nilotinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + nilotinib

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• nimodipine
Mezofy (aripiprazole)

+

nimodipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nimodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nirogacestat
Mezofy (aripiprazole)

+

nirogacestat

1 interaction

Monitor/Modify Tx

aripiprazole oral + nirogacestat

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• nisoldipine
Mezofy (aripiprazole)

+

nisoldipine

1 interaction

Monitor/Modify Tx

aripiprazole oral + nisoldipine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nitric oxide
Mezofy (aripiprazole)

+

nitric oxide

1 interaction

Monitor/Modify Tx

aripiprazole oral + nitric oxide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• nitrite
Mezofy (aripiprazole)

+

nitrite

1 interaction

Monitor/Modify Tx

aripiprazole oral + nitrite

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nitroglycerin
Mezofy (aripiprazole)

+

nitroglycerin

1 interaction

Monitor/Modify Tx

aripiprazole oral + nitroglycerin

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• nitroprusside
Mezofy (aripiprazole)

+

nitroprusside

1 interaction

Monitor/Modify Tx

aripiprazole oral + nitroprusside

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis (additive effects)

• nortriptyline
Mezofy (aripiprazole)

+

nortriptyline

1 interaction

Monitor/Modify Tx

aripiprazole oral + nortriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• obinutuzumab
Mezofy (aripiprazole)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

aripiprazole oral + obinutuzumab

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• oliceridine
Mezofy (aripiprazole)

+

oliceridine

1 interaction

Monitor/Modify Tx

aripiprazole oral + oliceridine

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• olmesartan medoxomil
Mezofy (aripiprazole)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

aripiprazole oral + olmesartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• opicapone
Mezofy (aripiprazole)

+

opicapone

1 interaction

Monitor/Modify Tx

aripiprazole oral + opicapone

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• opium
Mezofy (aripiprazole)

+

opium

1 interaction

Monitor/Modify Tx

aripiprazole oral + opium

monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxazepam
Mezofy (aripiprazole)

+

oxazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + oxazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• oxybutynin
Mezofy (aripiprazole)

+

oxybutynin

1 interaction

Monitor/Modify Tx

aripiprazole oral + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxycodone
Mezofy (aripiprazole)

+

oxycodone

1 interaction

Monitor/Modify Tx

aripiprazole oral + oxycodone

monitor BP, respiratory rate; decr. oxycodone start dose by at least 50%, consider decr. aripiprazole dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• oxymorphone
Mezofy (aripiprazole)

+

oxymorphone

1 interaction

Monitor/Modify Tx

aripiprazole oral + oxymorphone

monitor respiratory rate, BP; decr. oxymorphone start dose by at least 50%, consider decr. aripiprazole dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• palopegteriparatide
Mezofy (aripiprazole)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

aripiprazole oral + palopegteriparatide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• paroxetine
Mezofy (aripiprazole)

+

paroxetine

1 interaction

Monitor/Modify Tx

aripiprazole oral + paroxetine

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• pentamidine
Mezofy (aripiprazole)

+

pentamidine

1 interaction

Monitor/Modify Tx

aripiprazole oral + pentamidine

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis (additive effects)

• pentazocine
Mezofy (aripiprazole)

+

pentazocine

1 interaction

Monitor/Modify Tx

aripiprazole oral + pentazocine

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• pentobarbital
Mezofy (aripiprazole)

+

pentobarbital

1 interaction

Monitor/Modify Tx

aripiprazole oral + pentobarbital

monitor BP, respiratory rate; double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (hepatic metabolism induced; additive effects)

• perindopril
Mezofy (aripiprazole)

+

perindopril

1 interaction

Monitor/Modify Tx

aripiprazole oral + perindopril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• perphenazine
Mezofy (aripiprazole)

+

perphenazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + perphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, severe hypotension, including orthostasis, syncope (additive effects)

• phenobarbital
Mezofy (aripiprazole)

+

phenobarbital

1 interaction

Monitor/Modify Tx

aripiprazole oral + phenobarbital

monitor respiratory rate, BP; double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• phenoxybenzamine
Mezofy (aripiprazole)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

aripiprazole oral + phenoxybenzamine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• phentolamine
Mezofy (aripiprazole)

+

phentolamine

1 interaction

Monitor/Modify Tx

aripiprazole oral + phentolamine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• phenytoin
Mezofy (aripiprazole)

+

phenytoin

1 interaction

Monitor/Modify Tx

aripiprazole oral + phenytoin

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• pindolol
Mezofy (aripiprazole)

+

pindolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + pindolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• pioglitazone
Mezofy (aripiprazole)

+

pioglitazone

1 interaction

Monitor/Modify Tx

aripiprazole oral + pioglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• posaconazole
Mezofy (aripiprazole)

+

posaconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + posaconazole

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• pramipexole
Mezofy (aripiprazole)

+

pramipexole

1 interaction

Monitor/Modify Tx

aripiprazole oral + pramipexole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• pramlintide
Mezofy (aripiprazole)

+

pramlintide

1 interaction

Monitor/Modify Tx

aripiprazole oral + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• prazosin
Mezofy (aripiprazole)

+

prazosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + prazosin

monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pregabalin
Mezofy (aripiprazole)

+

pregabalin

1 interaction

Monitor/Modify Tx

aripiprazole oral + pregabalin

monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• primidone
Mezofy (aripiprazole)

+

primidone

1 interaction

Monitor/Modify Tx

aripiprazole oral + primidone

monitor respiratory rate; double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• procarbazine
Mezofy (aripiprazole)

+

procarbazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + procarbazine

monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• prochlorperazine
Mezofy (aripiprazole)

+

prochlorperazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + prochlorperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, hypotension, including orthostasis (additive effects)

• propafenone
Mezofy (aripiprazole)

+

propafenone

1 interaction

Monitor/Modify Tx

aripiprazole oral + propafenone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• propofol
Mezofy (aripiprazole)

+

propofol

1 interaction

Monitor/Modify Tx

aripiprazole oral + propofol

monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis (additive effects)

• propranolol
Mezofy (aripiprazole)

+

propranolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + propranolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• protriptyline
Mezofy (aripiprazole)

+

protriptyline

1 interaction

Monitor/Modify Tx

aripiprazole oral + protriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• quazepam
Mezofy (aripiprazole)

+

quazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + quazepam

monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• quinapril
Mezofy (aripiprazole)

+

quinapril

1 interaction

Monitor/Modify Tx

aripiprazole oral + quinapril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• quinidine (antiarrhythmic)
Mezofy (aripiprazole)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

aripiprazole oral + quinidine (antiarrhythmic)

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• quinidine (CYP2D6 inhibitor)
Mezofy (aripiprazole)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

aripiprazole oral + quinidine (CYP2D6 inhibitor)

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• ramipril
Mezofy (aripiprazole)

+

ramipril

1 interaction

Monitor/Modify Tx

aripiprazole oral + ramipril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• rasagiline
Mezofy (aripiprazole)

+

rasagiline

1 interaction

Monitor/Modify Tx

aripiprazole oral + rasagiline

monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• remifentanil
Mezofy (aripiprazole)

+

remifentanil

1 interaction

Monitor/Modify Tx

aripiprazole oral + remifentanil

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• remimazolam
Mezofy (aripiprazole)

+

remimazolam

1 interaction

Monitor/Modify Tx

aripiprazole oral + remimazolam

monitor BP, respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of hypotension (including orthostasis), profound CNS and respiratory depression, psychomotor impairment (additive effects)

• repaglinide
Mezofy (aripiprazole)

+

repaglinide

1 interaction

Monitor/Modify Tx

aripiprazole oral + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• ribociclib
Mezofy (aripiprazole)

+

ribociclib

1 interaction

Monitor/Modify Tx

aripiprazole oral + ribociclib

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• rifabutin
Mezofy (aripiprazole)

+

rifabutin

1 interaction

Monitor/Modify Tx

aripiprazole oral + rifabutin

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• rifampin
Mezofy (aripiprazole)

+

rifampin

1 interaction

Monitor/Modify Tx

aripiprazole oral + rifampin

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Mezofy (aripiprazole)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + rilzabrutinib

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• riociguat
Mezofy (aripiprazole)

+

riociguat

1 interaction

Monitor/Modify Tx

aripiprazole oral + riociguat

monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)

• ritonavir
Mezofy (aripiprazole)

+

ritonavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + ritonavir

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• rolapitant
Mezofy (aripiprazole)

+

rolapitant

1 interaction

Monitor/Modify Tx

aripiprazole oral + rolapitant

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• ropinirole
Mezofy (aripiprazole)

+

ropinirole

1 interaction

Monitor/Modify Tx

aripiprazole oral + ropinirole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• ropivacaine
Mezofy (aripiprazole)

+

ropivacaine

1 interaction

Monitor/Modify Tx

aripiprazole oral + ropivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• rosiglitazone
Mezofy (aripiprazole)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

aripiprazole oral + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rotigotine transdermal
Mezofy (aripiprazole)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

aripiprazole oral + rotigotine transdermal

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• sacubitril
Mezofy (aripiprazole)

+

sacubitril

1 interaction

Monitor/Modify Tx

aripiprazole oral + sacubitril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• safinamide
Mezofy (aripiprazole)

+

safinamide

1 interaction

Monitor/Modify Tx

aripiprazole oral + safinamide

monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• saxagliptin
Mezofy (aripiprazole)

+

saxagliptin

1 interaction

Monitor/Modify Tx

aripiprazole oral + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• selegiline
Mezofy (aripiprazole)

+

selegiline

1 interaction

Monitor/Modify Tx

aripiprazole oral + selegiline

monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Mezofy (aripiprazole)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

aripiprazole oral + selegiline transdermal

monitor BP: combo may incr. risk of hypotension (including orthostasis), CNS depression, psychomotor impairment (additive effects)

• semaglutide
Mezofy (aripiprazole)

+

semaglutide

1 interaction

Monitor/Modify Tx

aripiprazole oral + semaglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sevoflurane
Mezofy (aripiprazole)

+

sevoflurane

1 interaction

Monitor/Modify Tx

aripiprazole oral + sevoflurane

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• sildenafil
Mezofy (aripiprazole)

+

sildenafil

1 interaction

Monitor/Modify Tx

aripiprazole oral + sildenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• silodosin
Mezofy (aripiprazole)

+

silodosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + silodosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sitagliptin
Mezofy (aripiprazole)

+

sitagliptin

1 interaction

Monitor/Modify Tx

aripiprazole oral + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sodium ferric gluconate complex
Mezofy (aripiprazole)

+

sodium ferric gluconate complex

1 interaction

Monitor/Modify Tx

aripiprazole oral + sodium ferric gluconate complex

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• sotagliflozin
Mezofy (aripiprazole)

+

sotagliflozin

1 interaction

Monitor/Modify Tx

aripiprazole oral + sotagliflozin

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• sotalol
Mezofy (aripiprazole)

+

sotalol

1 interaction

Monitor/Modify Tx

aripiprazole oral + sotalol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• sparsentan
Mezofy (aripiprazole)

+

sparsentan

1 interaction

Monitor/Modify Tx

aripiprazole oral + sparsentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• spironolactone
Mezofy (aripiprazole)

+

spironolactone

1 interaction

Monitor/Modify Tx

aripiprazole oral + spironolactone

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• St. John's wort
Mezofy (aripiprazole)

+

St. John's wort

1 interaction

Monitor/Modify Tx

aripiprazole oral + St. John's wort

double PO aripiprazole dose over 1-2wk; no dose adjustment if depression adjunct tx use: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• sufentanil
Mezofy (aripiprazole)

+

sufentanil

1 interaction

Monitor/Modify Tx

aripiprazole oral + sufentanil

monitor BP, respiratory rate, decr. sufentanil start dose, consider decr. aripiprazole dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• suvorexant
Mezofy (aripiprazole)

+

suvorexant

1 interaction

Monitor/Modify Tx

aripiprazole oral + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tadalafil
Mezofy (aripiprazole)

+

tadalafil

1 interaction

Monitor/Modify Tx

aripiprazole oral + tadalafil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• tagraxofusp
Mezofy (aripiprazole)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

aripiprazole oral + tagraxofusp

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• tamsulosin
Mezofy (aripiprazole)

+

tamsulosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + tamsulosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tapentadol
Mezofy (aripiprazole)

+

tapentadol

1 interaction

Monitor/Modify Tx

aripiprazole oral + tapentadol

monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• taurine
Mezofy (aripiprazole)

+

taurine

1 interaction

Monitor/Modify Tx

aripiprazole oral + taurine

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• telmisartan
Mezofy (aripiprazole)

+

telmisartan

1 interaction

Monitor/Modify Tx

aripiprazole oral + telmisartan

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• temazepam
Mezofy (aripiprazole)

+

temazepam

1 interaction

Monitor/Modify Tx

aripiprazole oral + temazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• terazosin
Mezofy (aripiprazole)

+

terazosin

1 interaction

Monitor/Modify Tx

aripiprazole oral + terazosin

monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• terbinafine
Mezofy (aripiprazole)

+

terbinafine

1 interaction

Monitor/Modify Tx

aripiprazole oral + terbinafine

decr. PO aripiprazole dose 50%; if also combined w/ strong CYP3A4 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• thioridazine
Mezofy (aripiprazole)

+

thioridazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + thioridazine

monitor BP; consider decr. dose of one or both drugs; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of CNS depression, psychomotor impairment, hyperthermia, hypotension (including orthostasis), other adverse effects (hepatic metabolism inhibited, additive effects)

• thiothixene
Mezofy (aripiprazole)

+

thiothixene

1 interaction

Monitor/Modify Tx

aripiprazole oral + thiothixene

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• timolol
Mezofy (aripiprazole)

+

timolol

1 interaction

Monitor/Modify Tx

aripiprazole oral + timolol

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• timolol ophthalmic
Mezofy (aripiprazole)

+

timolol ophthalmic

1 interaction

Monitor/Modify Tx

aripiprazole oral + timolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• tipranavir
Mezofy (aripiprazole)

+

tipranavir

1 interaction

Monitor/Modify Tx

aripiprazole oral + tipranavir

consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• tirzepatide
Mezofy (aripiprazole)

+

tirzepatide

1 interaction

Monitor/Modify Tx

aripiprazole oral + tirzepatide

monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tizanidine
Mezofy (aripiprazole)

+

tizanidine

1 interaction

Monitor/Modify Tx

aripiprazole oral + tizanidine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tolcapone
Mezofy (aripiprazole)

+

tolcapone

1 interaction

Monitor/Modify Tx

aripiprazole oral + tolcapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• torsemide
Mezofy (aripiprazole)

+

torsemide

1 interaction

Monitor/Modify Tx

aripiprazole oral + torsemide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• tramadol
Mezofy (aripiprazole)

+

tramadol

1 interaction

Monitor/Modify Tx

aripiprazole oral + tramadol

monitor BP, respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, seizures, severe hypotension, including orthostasis, syncope (additive effects)

• trandolapril
Mezofy (aripiprazole)

+

trandolapril

1 interaction

Monitor/Modify Tx

aripiprazole oral + trandolapril

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• trazodone
Mezofy (aripiprazole)

+

trazodone

1 interaction

Monitor/Modify Tx

aripiprazole oral + trazodone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• treprostinil
Mezofy (aripiprazole)

+

treprostinil

1 interaction

Monitor/Modify Tx

aripiprazole oral + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• triamterene
Mezofy (aripiprazole)

+

triamterene

1 interaction

Monitor/Modify Tx

aripiprazole oral + triamterene

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• triazolam
Mezofy (aripiprazole)

+

triazolam

1 interaction

Monitor/Modify Tx

aripiprazole oral + triazolam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• trifluoperazine
Mezofy (aripiprazole)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

aripiprazole oral + trifluoperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, extrapyramidal symptoms, severe hypotension, including orthostasis (additive effects)

• trimipramine
Mezofy (aripiprazole)

+

trimipramine

1 interaction

Monitor/Modify Tx

aripiprazole oral + trimipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis (additive effects)

• tucatinib
Mezofy (aripiprazole)

+

tucatinib

1 interaction

Monitor/Modify Tx

aripiprazole oral + tucatinib

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• valsartan
Mezofy (aripiprazole)

+

valsartan

1 interaction

Monitor/Modify Tx

aripiprazole oral + valsartan

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• vardenafil
Mezofy (aripiprazole)

+

vardenafil

1 interaction

Monitor/Modify Tx

aripiprazole oral + vardenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• verapamil
Mezofy (aripiprazole)

+

verapamil

1 interaction

Monitor/Modify Tx

aripiprazole oral + verapamil

monitor BP; consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of hypotension (including orthostasis), other adverse effects (hepatic metabolism inhibited, additive effects)

• voriconazole
Mezofy (aripiprazole)

+

voriconazole

1 interaction

Monitor/Modify Tx

aripiprazole oral + voriconazole

decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• vosoritide
Mezofy (aripiprazole)

+

vosoritide

1 interaction

Monitor/Modify Tx

aripiprazole oral + vosoritide

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

• yohimbe
Mezofy (aripiprazole)

+

yohimbe

1 interaction

Monitor/Modify Tx

aripiprazole oral + yohimbe

monitor BP, especially w/ high yohimbe doses: combo may incr. risk of hypotension, including orthostasis (additive effects)

• zaleplon
Mezofy (aripiprazole)

+

zaleplon

1 interaction

Monitor/Modify Tx

aripiprazole oral + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Mezofy (aripiprazole)

+

ziconotide

1 interaction

Monitor/Modify Tx

aripiprazole oral + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Mezofy (aripiprazole)

+

zolpidem

1 interaction

Monitor/Modify Tx

aripiprazole oral + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)